Reference: Shimabukuro, T. T., Kim, S. Y., Myers, T. R., Moro, P. L., Oduyebo, T., Panagiotakopoulos, L., … & Meaney-Delman, D. M. (2021). Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. New England Journal of Medicine, 384(24), 2273-2282. https://doi.org/10.1056/NEJMoa2104983 Summary: The article evaluates the safety of mRNA Covid-19 vaccines in pregnant individuals, utilising […]
Reference: Front Line COVID-19 Critical Care Alliance. (2021). Prevention & treatment protocols for COVID-19: Management protocol for Long Haul COVID-19 Syndrome (LHCS). Retrieved from https://flccc.net/flccc-protocols-a-guide-to-the-management-of-covid-19 Summary: The Front Line COVID-19 Critical Care Alliance (FLCCC) has developed a consensus protocol for managing Long Haul COVID-19 Syndrome (LHCS), which presents a range of symptoms including fatigue, cognitive
Reference: Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., Offergeld, K., Scheper, G., Taylor, K. L., Robb, M. L., Treanor, J., Barouch, D. H., Stoddard, J., Ryser, M. F., Marovich, M. A., Neuzil, K. M., Corey, L., Cauwenberghs, N., Tanner, T., Hardt,
Reference: De Marco Verissimo, C., O’Brien, C., López Corrales, J., Dorey, A., Cwiklinski, K., Lalor, R., … & Doyle, S. (2021). Improved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA tests. Epidemiology and Infection, 149, e140, 1–11. https://doi.org/10.1017/S0950268821001308 Summary: The article discusses advancements in diagnosing SARS-CoV-2 through the
Reference: Kamber Zaidi, A., & Dehgani-Mobaraki, P. (2021). The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article. The Journal of Antibiotics, 74(7), 441-454. https://doi.org/10.1038/s41429-021-00430-5 Summary: This review article examines the potential of Ivermectin as a therapeutic agent against SARS-CoV-2 amidst the COVID-19 pandemic. It highlights Ivermectin’s mechanism of action, including its
Reference: Chetty, S. (2021). Dr Chetty’s 8th day therapy for COVID-19. Covexit. Retrieved from [URL] Summary: Dr Shankara Chetty’s 8th Day Therapy for COVID-19 addresses the inflammatory phase occurring after Day 8 of infection, aiming to prevent severe disease progression. The document outlines four key interventions starting at this critical juncture. First, corticosteroids like Prednisone
Reference: FLCCC Alliance. (2021). I-MASS protocol. Retrieved from https://flccc.net/covid-19-protocols/ Summary: The I-MASS protocol, developed by the Front Line COVID-19 Critical Care Alliance (FLCCC), outlines prevention and treatment strategies for COVID-19, particularly focusing on home treatment and mass distribution during outbreaks. For prevention, adults over 18 years are advised to take Ivermectin (18 mg weekly), Vitamin
Reference: Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., … & Madhi, S. A. (2021). Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. The New England Journal of Medicine, 384(20), 1899-1909. https://doi.org/10.1056/NEJMoa2103055 Summary: The NVX-CoV2373 nanoparticle vaccine was evaluated in a phase 2 trial in South Africa during the B.1.351
Reference: Mair, V. (2021, April 30). Merriam-Webster gives “vaccine” a new definition. Language Log. Retrieved from https://languagelog.ldc.upenn.edu/nll/?p=50886 Summary: In a recent post, Victor Mair discusses an update to the definition of “vaccine” by Merriam-Webster. While traditional definitions describe vaccines as preparations of weakened or killed pathogens, the new entry expands this definition significantly. It now
Reference: South African Medical Research Council. (2021). Sisonke Protocol Version 4.4 dated 29 Apr 2021. Summary: The Sisonke Protocol is an open-label, single-arm phase 3B study aimed at evaluating the effectiveness of the Ad26.COV2.S COVID-19 vaccine among healthcare workers in South Africa. This study involves approximately 500,000 healthcare workers aged 18 and older, who will